Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI France ETF (EWQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

iShares MSCI France ETFTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI France ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI France ETF trades at $47.52, while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: iShares MSCI France ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

EWQRXRX
Sector
Broad Market / FactorHealth
52-Week High
$48.35$6.79
52-Week Low
$41.68$2.84
Market Cap
$1.81B
Enterprise Value
$1.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI France ETF

EWQ, the iShares MSCI France ETF, trades at $47.505, down 0.51% on the day, with a bullish technical signal driven by moving averages. The ETF focuses on French equities, particularly industrials, and offers a dividend scheduled for June 2026. Recent news highlights ECB rate decisions and French tech investments, influencing sentiment.

The outlook for EWQ is supported by bullish technicals and positive analyst views on French stocks, but risks include ECB policy shifts and geopolitical tensions. Investors may find opportunity in Europe's cyclical recovery, though volatility from energy prices and economic data poses challenges.

Recursion Pharmaceuticals Inc

RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.

Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI France ETF

EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.

Read more on EWQ

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX